November 21, 2017
Transparency and guidance by managements can escort investors out of the current maze of negative sentiment!
Investors want to know, will forgive if there’s a substance beyond the words of the message
Pre-open trading indications: 3 SELLs and 2 BUYs:
Can’t read because of no subscription rights - you’re missing situational awareness and the most trustworthy source of independent insight!
October 29, 2017
For continued access to what one industry CEO calls the “bible” for smart investing in the RegMed, gene and cell therapy sector, click the link:
Learn who is stumbling and what the mumbling means!
October 23, 2017
QURE was priced at $18.25 per share
October 13, 2017
Are day traders ready for the filed 8-K as BSTG conducted a reduction in headcount …
November 21, 2017
As the sector opens up, slips at the mid-day and closes down
While the iShares Nasdaq Biotechnology ETF (IBB) closed up +0.77%
Earnings season is winding down and most companies have missed expectations and that's a negative for the sector
Daily pre-open indications: 0 hit and 5 miss (still made $)
Quarterly results: IMUC
How right does one have to be? You could and should be reading this review of the day’s share pricing activity?
Is the truth so hard to fathom – that’s why my readership has grown exponentially!
November 16, 2017
AXGN is down -$2.95 or -11.85% after closing at $24.90
November 14, 2017
Thirty four (34) as of today ... so far Financial results also known as (AKA) earnings are a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.
October 30, 2017
NASDAQ shares drop -$0.31 or -15.98% to $1.66
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
3 hours 27 min ago
RegMed Investors’ (RMi) closing bell; just another melt down
13 hours 20 min ago
RegMed Investors’ (RMi) pre-open indications; the current sector resistance